Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab continuation with crossover fluoropyrimidine chemotherapy in metastatic colorectal cancer after progression on first-line bevacizumab + chemotherapy
2006-004634-32Phase 3Completed
- Sponsor
- Roche
- Start
- Oct 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bevacizumab in metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Roche. Primary endpoints: Overall survival from randomization and Overall survival from start of first-line therapy. Started Oct 2006; status: completed.
02
Drugs
bevacizumab
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2006-004634-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004634-32.